12 studies found for:    Mepolizumab | asthma | Phase 3
Show Display Options
Rank Status Study
1 Recruiting Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Condition: Asthma
Interventions: Biological: Mepolizumab 100mg;   Drug: Placebo
2 Unknown  Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations
Conditions: Asthma;   Viral Infection
Interventions: Drug: Mepolizumab;   Drug: Placebo
3 Completed
Has Results
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
Condition: Asthma
Interventions: Drug: Mepolizumab IV;   Drug: Mepolizumab SC;   Drug: IV Placebo;   Drug: SC Placebo
4 Completed
Has Results
Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
Condition: Asthma
Interventions: Drug: Mepolizumab;   Drug: Placebo;   Drug: OCS (prednisone/prednisolone)
5 Completed Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
Condition: Asthma
Interventions: Biological: Mepolizumab;   Drug: Placebo;   Drug: SOC
6 Recruiting Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study
Condition: Asthma
Interventions: Drug: Mepolizumab;   Drug: Placebo
7 Active, not recruiting A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
Condition: Asthma
Interventions: Biological: Mepolizumab;   Drug: SOC
8 Recruiting A Long-term Access Programme for Subjects With Severe Asthma
Condition: Asthma
Intervention: Drug: Mepolizumab 40mg or 100mg
9 Completed
Has Results
A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
Condition: Asthma
Intervention: Biological: Mepolizumab
10 Active, not recruiting MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
Condition: Asthma
Intervention: Drug: Mepolizumab
11 Completed Cross-sectional Study for Identification and Description of Severe Asthma Patients
Condition: Asthma
Intervention: Drug: Short Acting Beta Agonist (SABA)
12 Enrolling by invitation Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma
Conditions: Severe Persistent Asthma;   Eosinophilic Bronchitis
Interventions: Biological: Reslizumab;   Drug: Placebo

Indicates status has not been verified in more than two years